Lucid Diagnostics (LUCD), a unit of PAVmed (PAVM), said Tuesday it agreed to sell 13.9 million shares at $1.10 each in a registered direct offering.
Gross proceeds are anticipated to total $15.3 million and the transaction is expected to close on Wednesday, the company said.
Lucid Diagnostics said net proceeds will be used for working capital and general corporate purposes.
The company's shares were down nearly 18% in recent Tuesday premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.